X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Galapagos will have the option to license Adaptimmune’s next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications.
Lead Product(s): Uzatresgene Autoleucel,Nivolumab
Therapeutic Area: Oncology Product Name: ADP-A2M4CD8
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Galapagos
Deal Size: $565.0 million Upfront Cash: $70.0 million
Deal Type: Collaboration May 30, 2024
Details:
The proceeds will be used for the commercial launch of ADP-A2M4 (afamitresgene autoleucel), directed to MAGE family of cancer testis antigens expressed in a number of solid tumor cell types.
Lead Product(s): Afamitresgene Autoleucel
Therapeutic Area: Oncology Product Name: ADP-A2M4
Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Hercules Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing May 15, 2024
Details:
The combined company will utilize engineered T-cell therapies targeting MAGE-A4 and mesothelin. These targets are expressed on a broad range of solid tumors and are supported by compelling early- and late-stage clinical data.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TCR2 Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 06, 2023
Details:
44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers.
Lead Product(s): ADP-A2M4CD8
Therapeutic Area: Oncology Product Name: ADP-A2M4CD8
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
Adaptimmune applied their lentiviral technology to TILs engineering them to express IL-7 (ADP-TILIL7) intended to improve clinical responses, produced levels of IL-7 shown to improve growth and survival in vitro.
Lead Product(s): ADP-TILIL7
Therapeutic Area: Oncology Product Name: ADP-TILIL7
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
Results from this large dataset are consistent with data previously shared by the Company and support MAGE-A4 as an important cancer target within the tumor types currently included in ongoing clinical trials of afami-cel and ADP-A2M4CD8.
Lead Product(s): Afamitresgene Autoleucel
Therapeutic Area: Oncology Product Name: ADP-A2M4
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Post-infusion biopsies indicated that infiltrating afami-cel SPEAR T-cells co-localize with tumor and additional immune cells, with evidence of activated and proliferative state and adaptive-immune response.
Lead Product(s): Afamitresgene Autoleucel
Therapeutic Area: Oncology Product Name: SPEAR T Cells
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
Details:
Afamitresgene autoleucel or ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.
Lead Product(s): ADP-A2M4CD8
Therapeutic Area: Oncology Product Name: ADP-A2M4CD8
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2021
Details:
Adaptimmune will be responsible for developing clinical candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to develop allogeneic T-cell therapies for up to five shared cancer targets and personalized allogeneic T-cell therapies.
Lead Product(s): Allogeneic T-cell Therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $3,300.0 million Upfront Cash: $150.0 million
Deal Type: Collaboration September 07, 2021
Details:
The study revealed that DP-A2AFP has an acceptable safety profile with no reports of significant T-cell related hepatotoxicity and no protocol-defined dose limiting toxicities.
Lead Product(s): Autologous Genetically Modified AFPᶜ³³²T Cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
